Results 11 to 20 of about 12,232 (185)

PCSK9 inhibitors for acute coronary syndrome: the era of early implementation

Frontiers in Cardiovascular Medicine, 2023
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a new cholesterol-lowering strategy, can decrease low-density lipoprotein cholesterol (LDL-C) levels by inhibiting PCSK9 and reducing the degradation of LDL receptors; thus, they are ...
Hongzhen Chen, Xiaomin Chen
doaj   +1 more source

Naturally Occurring PCSK9 Inhibitors [PDF]

Nutrients, 2020
Genetic, epidemiological and pharmacological data have led to the conclusion that antagonizing or inhibiting Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces cardiovascular events. This clinical outcome is mainly related to the pivotal role of PCSK9 in controlling low-density lipoprotein (LDL) cholesterol levels.
Maria Pia Adorni, Francesca Zimetti, Maria Giovanna Lupo, Massimiliano Ruscica, Nicola Ferri   +4 more
openaire   +5 more sources

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism

Hepatology, EarlyView., 2022
Hepatic APOF transcript levels correlate inversely with plasma TG and hepatic steatosis in humans. ApoF expression in mice promotes VLDL‐TG production and lipoprotein remnant clearance in mice. Abstract Background NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD,
Audrey Deprince, Nathalie Hennuyer, Sander Kooijman, Amanda C. M. Pronk, Eric Baugé, Viktor Lienard, An Verrijken, Eveline Dirinck, Luisa Vonghia, Eloïse Woitrain, Niels J. Kloosterhuis, Eléonore Marez, Pauline Jacquemain, Justina C. Wolters, Fanny Lalloyer, Delphine Eberlé, Sandrine Quemener, Emmanuelle Vallez, Anne Tailleux, Mostafa Kouach, Jean‐Francois Goossens, Violeta Raverdy, Bruno Derudas, Jan Albert Kuivenhoven, Mikaël Croyal, Bart van de Sluis, Sven Francque, François Pattou, Patrick C. N. Rensen, Bart Staels, Joel T. Haas   +30 more
wiley   +1 more source

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance

Безопасность и риск фармакотерапии, 2023
Scientific relevance. The main cause of cardiovascular pathologies is atherosclerosis, which is secondary to lipid metabolism disorders, in particular, the accumulation of low-density lipoprotein (LDL) cholesterol.
K. O. Shnaider, M. L. Maximov, V. A. Baranova, A. A. Nekipelova   +3 more
doaj   +1 more source

PCSK9 inhibitors for hypercholesterolaemia [PDF]

BMJ, 2017
New drugs, old problems Statins (hydroxymethyl-glutaryl coenzyme A reductase inhibitors) reduce “bad” low density lipoprotein (LDL) cholesterol concentrations and cardiovascular risk. So too, do better diet and more exercise, which together almost halve rates of coronary event rates when compared with an “unfavourable lifestyle.”3 For some people ...
Patricia, McGettigan, Robin E, Ferner
openaire   +2 more sources

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System

Cardiovascular Therapeutics, 2022
Background. Some studies suggest that potential safety issues about PCSK9 inhibitors have not been sufficiently explored in clinical trials, including musculoskeletal adverse events (MAEs). Objective.
Lingqing Ding, Congqin Chen, Yongkuan Yang, Jie Fang, Longxing Cao, Yige Liu   +5 more
doaj   +1 more source

Real-world data on the prescription of proprotein convertase subtilisin/kexin type 9 inhibitors in high-risk patients in a tertiary medical center

Journal of the Formosan Medical Association, 2022
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, are currently approved for clinical use by Taiwan National Health Insurance (NHI) in patients who had a recent atherosclerotic cardiovascular disease with ...
Chia-Ling Tsai, Ya-Hui Chang, Cheng-Huang Su, Yih-Jer Wu, Hung-I Yeh, Chao-Feng Lin   +5 more
doaj   +1 more source

PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center

Рациональная фармакотерапия в кардиологии, 2022
Aim. To characterize patients receiving PCSK9 inhibitors, and assess the efficiency of their treatment in a specialized lipid center.Material and methods.
A. V. Blokhina, A. I. Ershova, A. S. Limonova, O. V. Kopylova, A. N. Meshkov, O. M. Drapkina   +5 more
doaj   +1 more source

A Comprehensive Review of PCSK9 Inhibitors

Journal of Cardiovascular Pharmacology and Therapeutics, 2022
Cardiovascular disease (CVD) is the leading cause of death in the United States and worldwide. A major risk factor for this condition is increased serum low-density lipoprotein cholesterol (LDL-C) levels for which statins have been successful in reducing serum LDL-C to healthy concentrations.
Caroline Coppinger, Mohammad Reza Movahed, Veronica Azemawah, Lee Peyton, James Gregory, Mehrnoosh Hashemzadeh   +5 more
openaire   +3 more sources

Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives. [PDF]

PLoS ONE, 2017
The introduction of Proprotein covertase subtilisin/kexin type 9 (PCSK9) inhibitors has been heralded as a major advancement in reducing low-density lipoprotein cholesterol levels by nearly 50%.
Alejandro Arrieta, Timothy F Page, Emir Veledar, Khurram Nasir   +3 more
doaj   +1 more source